Case Study December 17, 2025
Providing Project Management Support For Medical Device Supply Chain Disruptions
Trexin coordinated cross-functional efforts to mitigate financial risk and transition to alternative solutions.
Business Driver
Several large manufacturers announced plans to phase out certain chemicals within three years. These chemicals were used in a range of products across the medical device industry because of their reliable performance but faced increased regulatory scrutiny. Our Client faced significant pressure to identify alternative materials or solutions across their 4,000-supplier network to prevent disruptions to production lines and the associated revenue risks. Given Trexin’s expertise in supply chain management, medical technology project management, and supplier quality engineering, our Client engaged us to help navigate the situation and mitigate supply chain disruptions.
Approach
Trexin collaborated closely with our Client’s suppliers and business units to thoroughly assess the project scope and associated risks, while proposing and executing strategic solutions to minimize operational disruptions. Trexin led cross-functional project teams including supplier quality engineers, business unit leaders, supply chain managers, and executive stakeholders to define clear requirements for executing supplier change requests and implementing necessary adjustments to production lines. Recognizing that each supplier’s potential disruptions were unique, Trexin established a structured framework to define team workstreams and map workflows from project initiation to closure.
Results
Trexin successfully helped our Client transition 35 suppliers to alternative materials, covering 861 parts, 27 manufacturing sites, and 13 business units. This work exceeded client supply chain requirements and prevented potential production disruptions that could have resulted in tens of millions of dollars in lost revenue, effectively avoiding line-down scenarios. These efforts not only protected our Client’s production lines but also supported the medical technology industry’s move toward safer chemical alternatives.
